Clinical trials for Neuroendocrine tumours

Information provided by WHO International Clinical Trials Registry

The clinical trials below are relevant to Neuroendocrine tumours. For all clinical trials, go to clinical trials search

This list shows clinical trials for Neuroendocrine tumours

Search result filters
Recruitment status
Trials for children:
Country of trial:

You have searched for the following terms

  • Neuroendocrine tumours
Title Recruitment status Location
A low FODMAP diet for diarrhoea predominant functional gastrointestinal disorders in neuroendocrine tumour patients Recruiting United Kingdom
A Study to Assess Neuroendocrine Tumour (NET) Patients Currently Treated by Somatuline Autogel for History of Carcinoid Syndrome Associated With Episodes of Diarrhea Not recruiting United Kingdom
Registered phase I trial of vandetanib in combination with 131I-mIBG radiation therapy for patients with advanced or metastatic phaeochromocytoma or paraganglioma, to determine the recommended phase II dose of vandetanib. Not Recruiting United Kingdom
A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours Not recruiting United Kingdom
A randomised phase II study comparing capecitabine plus streptozocin with or without cisplatin in the treatment of unresectable or metastatic gastroentero-neuroendocrine tumours of the foregut, pancreatic neuroendocrine tumours and neuroendocrine tumours of unknown primary site Not Recruiting United Kingdom
An open-label, multicohort, phase II study of Atezolizumab in advanced solid tumors Authorised United Kingdom
An open-label, multicohort, phase II study of Atezolizumab in advanced solid tumors Authorised United Kingdom
A clinical trial to determine if there is a better order of giving everolimus and STZ-5FU in the treatment of advanced progressive pNETs. Authorised United Kingdom
A multicenter, stratified, open, randomized, comparator-controlled, parallelgroup phase III study. In this study, treatment with 177Lu-DOTA0-Tyr3-Octreotate plus best supportive care (30 mg Octreotide LAR) will be compared to treatment with high dose (60 mg) Octreotide LAR in patients with inoperable, somatostatin receptor positive, histologically proven midgut carcinoid tumours. Authorised United Kingdom
Randomized not blinded clinical trial to compare two sequences of treatment: STZ-5FU followed by everolimus or everolimus followed by STZ-5FU upon progression in advanced progressive pancreatic neuroendocrine tumors (SEQTOR study) Authorised United Kingdom

Page last reviewed: 04/11/2014

Next review due: 04/11/2017